# XBiotech Inc (XBIT)

> XBiotech Inc (XBIT) trades at $1.89 (+1.07%) as of 4:10:04 PM EST on Nov 6, 2026, -14.09% over the past month. Market cap is $57.62M, with 6.5 days to cover in short interest.

Canonical: https://massive.com/quote/xbit
Data as of: 2026-11-06T21:10:04.292Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.89** +0.02 (+1.07%)
As of 4:10:04 PM EST on Nov 6, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How XBiotech Inc (XBIT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.07% |
| 1W | +0.53% |
| 1M | -14.09% |
| YTD | -20.92% |
| 1Y | -22.86% |
| 52-wk range | $1.80 – $3.44 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for XBIT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.86 – $1.95 |
| Open | $1.88 |
| Prev close | $1.87 |
| Volume | 25.25K |
| Market cap | $57.62M |
| Shares out | 30.49M |

## Valuation and profitability ratios

Valuation and profitability ratios for XBiotech Inc: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.45 |
| P/FCF | — |
| ROE | -35.1% |
| ROA | -33.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 6, 2026

## Insider trading

[XBiotech Inc (XBIT) insider trading](https://massive.com/quote/xbit/insider-trading.md): open-market Form 4 buys and sells by XBiotech Inc insiders over the last 12 months.

## 8-K filings

Material corporate events XBiotech Inc has disclosed to the SEC on Form 8-K.

- Oct 26, 2026 · Ceo appointment
  “XBiotech announces that the Board of Directors has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard to serve as Co-Chief Executive Officers of the Company effective October 23, 2026.”
- Dec 9, 2025 · Ceo appointment
  “Sushma Shivaswamy, 47, who has served as XBiotech's Chief Scientific Officer since November 2017, has been appointed to serve as the Company's interim CEO effective December 8, 2025. Her annual base salary will be increased to $750,000 while she serves in these roles, with a bonus structure and a full remuneration package to be determined by the Compensation Committee at a later time.”
- Oct 3, 2025 · Executive compensation change
  “On October 2, 2025, John Simard and XBiotech, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement"), with an effective date of October 1, 2025, to replace and supersede all prior employment agreements between Mr. Simard and the Company. Under the Agreement, Mr. Simard will maintain his current annual Base Salary of USD $1,250,000. Mr. Simard will also be eligible to receive an annual Base Bonus of USD $4,530,442.00, which reflects the average annual bonus paid over the past 5 years.”
- Sep 2, 2025 · Annual meeting results
  “The annual meeting of the stockholders of XBiotech Inc. (the "Company") was held on August 29, 2025. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors' recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; (3) approve, on an advisory basis, the compensation of the Company's named executive officers; (4) approve the Company's 2025 Equity Incentive Plan.”
- Jun 24, 2025 · Director appointment
  “XBiotech Inc. announces the June 24, 2025 appointments of Dr. Thomas Kündig and Craig Rademaker to the Company's Board of Directors. Dr. Kündig has further been appointed to serve on the Compensation Committee, while Mr. Rademaker has been appointed to serve on the Audit Committee.”

## Dividend history and stock splits

XBiotech Inc's recent dividend payments and stock splits.

### Dividends

- $2.10 · ex-div Jul 15, 2021

### Splits

No recent splits.

## XBIT short interest

How heavily XBIT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.5 |
| Short interest | 300.91K |
| Avg volume | 46.45K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## XBIT news

The latest news and headlines about XBiotech Inc (XBIT).

- [XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux](https://www.globenewswire.com/news-release/2026/10/24/3387676/35550/fr/xbiotech-annonce-la-nomination-de-sushma-shivaswamy-et-jan-paul-simard-aux-postes-de-co-directeurs-g%C3%A9n%C3%A9raux.html) · GlobeNewswire Inc. · Oct 24, 2026 · positive sentiment
- [XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt](https://www.globenewswire.com/news-release/2026/10/24/3387676/35550/de/xbiotech-gibt-die-wahl-von-sushma-shivaswamy-und-jan-paul-simard-zu-co-chief-executive-officers-bekannt.html) · GlobeNewswire Inc. · Oct 24, 2026 · positive sentiment
- [XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire](https://www.globenewswire.com/news-release/2026/10/19/3383977/35550/fr/xbiotech-annonce-des-r%C3%A9sultats-d-efficacit%C3%A9-finaux-positifs-de-phase-ii-pour-l-essai-taskin-commandit%C3%A9-par-un-chercheur-dans-le-cancer-colorectal-m%C3%A9tastatique-r%C3%A9fractaire.html) · GlobeNewswire Inc. · Oct 19, 2026 · positive sentiment
- [XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom](https://www.globenewswire.com/news-release/2026/10/19/3383977/35550/de/xbiotech-gibt-positive-endg%C3%BCltige-wirksamkeitsergebnisse-der-phase-ii-studie-taskin-bekannt-einer-von-forschern-initiierten-studie-zur-behandlung-von-refrakt%C3%A4rem-metastasiertem-kol.html) · GlobeNewswire Inc. · Oct 19, 2026 · positive sentiment
- [XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer](https://www.globenewswire.com/news-release/2026/10/19/3383463/35550/en/xbiotech-announces-positive-phase-ii-final-efficacy-results-from-investigator-sponsored-taskin-trial-in-refractory-metastatic-colorectal-cancer.html) · GlobeNewswire Inc. · Oct 19, 2026 · positive sentiment

## About XBiotech Inc

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Listed | Apr 15, 2015 |

[Company website](http://www.xbiotech.com)

## FAQ

### What is the XBiotech Inc (XBIT) stock price today?

XBiotech Inc (XBIT) is trading at $1.89 (+1.07% on the day) as of 4:10:04 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is XBiotech Inc?

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases.

### What is the short interest in XBIT?

As of Oct 15, 2026, XBIT has 300.91K shares short and 6.5 days to cover.

### Does XBiotech Inc (XBIT) pay a dividend?

Yes. XBiotech Inc (XBIT)'s most recent dividend was $2.10 per share, with an ex-dividend date of Jul 15, 2021. Full XBIT dividend history is available from the Massive API.

### What exchange is XBIT listed on?

XBiotech Inc (XBIT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time XBIT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=XBIT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [XBiotech Inc (XBIT) insider trading](https://massive.com/quote/xbit/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms